Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

APTADEGRAD

Financiado

Cerrado

A novel first in its kind aptamer based LYTACs to address the unmet clinical n...

A novel first in its kind aptamer based LYTACs to address the unmet clinical need of diabetic wounds. Diabetic foot ulcers (DFUs) a major complication of diabetes, occur in ~25% of patients, with a five-year recurrence rate of ~65% . DFUs often end in hospitalization, with limb amputations in up to 60% of cases . DFU related mort... ver más

30/11/2027

LINCBIOTECH

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

LINCBIOTECH La investigación, desarrollo y comercialización de productos y servicios paa el sector biomédico. el desarrollo y comercialización de softwa...

TRL 5-6 | 240K€

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-11-25

HORIZON-EIC-2022-PATHFINDEROPEN-01-01: EIC Pathfinder Open 2022 Scope:You should apply to this call if you are looking for support from EIC Pathfinder Open to reali...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

LINCBIOTECH

714.38K€ | Lider

SYNABS

602.29K€ | Participante

UMINHO

600.53K€ | Participante

Proyectos interesantes

VascColl

Medical Technol...

Materials Scien...

188K€ Cerrado

WHILYAS

Medical Technol...

Pharmaceuticals

3M€ Cerrado

SAF2014-53763-P

Medical Technol...

Biotechnology

145K€ Cerrado

StrataGRT

Medical Technol...

Materials Scien...

71K€ Cerrado

PreventDFU

Medical Technol...

Medical Devices

1M€ Cerrado

XTremedy Medical

Medical Technol...

Surgical Techno...

75K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 60 meses Fecha Inicio: 2022-11-25
Fecha Fin: 2027-11-30

Líder del proyecto

LINCBIOTECH La investigación, desarrollo y comercialización de productos y servicios paa el sector biomédico. el desarrollo y comercialización de softwa...

TRL 5-6 | 240K€

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Diabetic foot ulcers (DFUs) a major complication of diabetes, occur in ~25% of patients, with a five-year recurrence rate of ~65% . DFUs often end in hospitalization, with limb amputations in up to 60% of cases . DFU related mortality is 5% within twelve months, rising to 42% after five years. Despite high prevalence and its major impact on the quality of life, no effective treatment has been approved, so DFU remain a highly unmet clinical condition. APTADEGRAD aims at obtaining in vivo proof-of-concept for a novel, first-in-class therapy using aptamer-based Lysosome Targeted Chimeras (LYTACs) to heal diabetic foot ulcers (DFUs). These LYTACs will target IL-1β, its receptor IL-1R1, and MMP-9 for degradation, proteins known to play a key role in impaired healing in diabetic wounds. Out hypothesis is that a) aptamer-based LYTACs MoA, may offer the potential to deliver a controlled, dose-dependent reduction of MMP9, IL-1b and its receptor IL-1R1, moderating the excessive DFU inflammatory response, while maintaining biologically beneficial levels of these proteins to promote healing and prevent infection; b) the simultaneous targeting of these relevant proteins will produce a synergetic effect in the inflammation cascade, providing superior efficacy outcomes. Should the main objective of the project is achieved (i.e. show efficacy in animal models of DFU), we would be showing for the first time a potential therapy based on LYTACs, in this case in the context of diabetic ulcers, with potential applications in other types of chronic wound or immune pathologies. In addition to efficacy data, we will be gathering essential knowledge about LYTACs (toxicity, efficacy, mechanism of action, differences with other approaches such as blocking or inhibition which are essential for successful future translation of the novel concept of LYTAC in pharmaceutical development to clinical trials.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores